GlycoMimetics, Inc.
GLYCNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for GLYC. That does not mean none is planned.
Get an email about GLYC's next catalysts
Track GlycoMimetics (GLYC) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
Market Overview
Stock performance and key metrics
Rivipansel
Anemia, Sickle Cell
GMI-1271
Leukemia, Myeloid, Acute
GMI-1070
Sickle Cell Disease
Uproleselan
Multiple Myeloma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Rivipansel | Phase 3 | Anemia, Sickle Cell | - | - |
GMI-1271 | Phase 2 | Leukemia, Myeloid, Acute | - | - |
GMI-1070 | Phase 2 | Sickle Cell Disease | - | - |
Uproleselan | Phase 2 | Multiple Myeloma | - | - |
Frequently asked questions
What is in GlycoMimetics, Inc.'s drug pipeline?β
CatalystAlert tracks 4 drug candidates in GlycoMimetics, Inc.'s (GLYC) pipeline across Phase 3, Phase 2. Its lead program is Rivipansel (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is GlycoMimetics, Inc.'s next FDA catalyst?β
CatalystAlert tracks every upcoming catalyst for GlycoMimetics, Inc. (GLYC) β PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β each confidence-rated as confirmed, estimated or AI-detected.
How do I track GLYC biotech catalysts?β
Add GLYC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow GlycoMimetics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
